Search results
Results from the WOW.Com Content Network
NVAX data by YCharts. Novavax's late-stage trials hit a snag. Novavax successfully developed a COVID-19 vaccine that is currently its only product on the market. The company has been working on ...
Kennedy has long railed against vaccines, once calling those that protect against Covid-19 a "crime against humanity." He has treaded more carefully in recent weeks, though, and has said he wouldn ...
An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%.
Moderna cut its 2025 forecast by $1 billion Monday, citing weak demand for its newest vaccine as well as slow sales for its COVID-19 vaccine. The company now expects $1.5 to $2 billion in revenue ...
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
Vaccine stocks continued to fall in premarket trading on Friday, following a sharp decline on Thursday after President-elect Donald Trump announced he would appoint Robert F. Kennedy Jr. to head ...
Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday ...
On November 1, Novavax, Inc. (NASDAQ:NVAX) and the U.K. Health Security Agency, representing the U.K. Secretary of State for Health and Social Care, signed a Termination and Settlement Agreement ...